StockData
Lakefront Biotherapeutics NV logo

Lakefront Biotherapeutics NV (LKFT) stock

LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
Financials through fiscal 2025, year ended Dec 31, 2025Score 7/30
$33.39−0.68 (-2.00%)

Close on Nov 19, 2026Market cap $2.20BP/E 6.2Yield –

Lakefront Biotherapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

For fiscal 2025 it was -€271.16M. The highest annual figure on record is €3.19B in fiscal 2019.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-€271.16M–
FY2024Dec 31, 2024-€336.75M–
FY2023Dec 31, 2023-€424.68M–
FY2022Dec 31, 2022-€527.93M–
FY2021Dec 31, 2021-€558.03M–
FY2020Dec 31, 2020-€469.86M-114.7%
FY2019Dec 31, 2019€3.19B–
FY2018Dec 31, 2018-€152.86M–
FY2017Dec 31, 2017-€152.34M-164.8%
FY2016Dec 31, 2016€234.95M–
FY2015Dec 31, 2015-€120.69M–

More Lakefront Biotherapeutics figures

See a number that looks wrong?